^
    5ms
    Detection of FGFR3 mutations and fusions in bladder cancer samples: Comparison of the MODAPLEX FGFR panel with therascreen FGFR Kit (ECP 2024)
    The MODAPLEX FGFR panel allows the stratification of bladder cancer patients by determination of the FGFR3 mutational and FGFR2/3 fusion status. The PCR-based FGFR assessment by MODAPLEX FGFR panel and therascreen FGFR kit is highly concordant (78/79). The MODAPLEX assays enable fast, local FGFR assessment in a multiplexed one-step approach within few hours.
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
    |
    Uromonitor®
    10ms
    NCCH2006/MK010 Trial (FORTUNE Trial) (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, National Cancer Center, Japan | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR4 (Fibroblast growth factor receptor 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR2 N549K • FGFR1 fusion • FGFR3 fusion • FGFR2 P253R • FGFR2 K310R • FGFR3 Y375C • FGFR2 C382R • FGFR2 N549D • FGFR2 N549H • FGFR2 S252W • FGFR2 Y375C • FGFR3 G380R • FGFR3 K650E • FGFR2 W290C
    |
    Tasfygo (tasurgratinib)
    over1year
    Infigratinib in Recurrent High-Grade Glioma Patients (clinicaltrials.gov)
    P1, N=7, Terminated, Nader Sanai | N=20 --> 7 | Trial completion date: Jul 2023 --> Apr 2023 | Active, not recruiting --> Terminated; Study drug no longer available.
    Enrollment change • Trial completion date • Trial termination
    |
    TACC3 (Transforming acidic coiled-coil containing protein 3) • CASP3 (Caspase 3)
    |
    FGFR3 mutation • FGFR3 K650E
    |
    Truseltiq (infigratinib)
    over1year
    Infigratinib in Recurrent High-Grade Glioma Patients (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Nader Sanai | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2023
    Enrollment closed • Trial primary completion date
    |
    TACC3 (Transforming acidic coiled-coil containing protein 3) • CASP3 (Caspase 3)
    |
    FGFR3 mutation • FGFR3 K650E
    |
    Truseltiq (infigratinib)
    almost2years
    PROOF 302: Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (clinicaltrials.gov)
    P3; N=218 --> 39 | Trial completion date: Jan 2025 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Jan 2023; The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.
    Trial completion date • Trial primary completion date • Enrollment change • Trial termination
    |
    FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
    |
    FoundationOne® CDx
    |
    Truseltiq (infigratinib)
    2years
    PROOF 302: Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (clinicaltrials.gov)
    P3; Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
    |
    FoundationOne® CDx
    |
    Truseltiq (infigratinib)
    over2years
    Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. (PubMed, Clin Cancer Res)
    FGFR inhibitor monotherapy with infigratinib had limited efficacy in a population of patients with recurrent gliomas and different FGFR genetic alterations, but durable disease control lasting more than 1 year was observed in patients with tumors harboring FGFR1 or FGFR3 point mutations or FGFR3‑TACC3 fusions. A follow-up study with refined biomarker inclusion criteria and centralized FGFR testing is warranted.
    P2 data • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3)
    |
    FGFR3-TACC3 fusion • FGFR3 mutation • FGFR1 fusion • FGFR3 fusion • FGFR3 K650E
    |
    Truseltiq (infigratinib)